It was demonstrated that ezetimibe, a small molecule compound used in the treatment of hypercholesterolemia, inhibits cholesterol absorption by binding to the second extracellular loop region of NPC1L1 to block the formation of endocytic vesicles [11, 17, 21, 22]. Here, NPC1L1 is linked to familial hypercholesterolemia.